By fits and starts, the market for initial public offerings is getting its footing. Of the four deals on tap this week, all are biotech operators. But among these offerings, there is one that is likely to stand out — Intellia Therapeutics.
Intellia plans to offer 5 million shares at a range of $16 to $18, and the lead underwriters include Credit Suisse Group AG (ADR) (CS), Jefferies and Leerink Partners. The proposed ticker stated in Intellia’s S1 form is NTLA.
The excitement for the IPO centers around Intellia’s Crispr-Cas9 technology, which is a naturally occurring defense mechanism in bacteria that fights against foreign DNA. Dr. Jennifer Doudna, a scientist at Berkeley, sees this as a way to potentially fight cancer and other diseases. Read